MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Clinical trial NCT05903092 · RECRUITING

Trial details

NCT number: NCT05903092
Sponsor: Hirva Mamdani
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer SCLC Extensive Stage Small Cell Lung Cancer Limited Stage Small-Cell Lung Cancer

Start date: 2023-09-26
Primary completion: 2029-10-31
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.